Back to Search
Start Over
Left atrial appendage occlusion devices vs direct oral anticoagulants for atrial fibrillation: An updated systematic review and meta-analysis.
- Source :
-
Current problems in cardiology [Curr Probl Cardiol] 2025 Jan; Vol. 50 (1), pp. 102880. Date of Electronic Publication: 2024 Oct 10. - Publication Year :
- 2025
-
Abstract
- Background: Direct Oral Anticoagulants (DOACs) are the first line anticoagulation for patients with non-valvular atrial fibrillation (NVAF). Percutaneous Left Atrial Appendage Occlusion (LAAO) has emerged as a new therapy and its safety and effectiveness compared with DOACs are still controversial.<br />Methods: A systematic review of randomized controlled trials and observational studies was conducted, focusing on patients with NVAF. Outcomes analyzed included: (1) all-cause mortality; (2) cardiovascular (CV) mortality; (3) thromboembolic events; (4) stroke or transient ischemic attack (TIA); (5) bleeding events; and a (6) composite of death, hemorrhagic, and thromboembolic events. We performed a subgroup analysis of major bleeding according to different definitions: (1) Bleeding Academic Research Consortium (BARC); (2) International Society on Thrombosis and Haemostasis (ISTH); and (3) other definitions.<br />Results: Ten studies involving 18,507 patients were included, with 42.35 % undergoing LAAO. In pooled analysis, LAAO was associated with lower rates of all-cause mortality (HR 0.63; 95 % CI 0.50-0.80), cardiovascular mortality (HR 0.56; 95 % CI 0.45-0.70), and of the composite outcome (HR 0.73; 95 % CI 0.58-0.92). A trend towards lower stroke/TIA events was observed but not statistically significant. Overall bleeding events did not significantly differ between groups; using the ISTH definition, LAAO showed significantly lower incidence of bleeding events (HR 0.63; 95 % CI 0.43-0.91). No difference was found in thromboembolic events.<br />Conclusion: LAAO was associated with a significantly lower all-cause mortality and cardiovascular mortality, as well as the composite of death, hemorrhagic or thromboembolic events, as compared with DOACs.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Subjects :
- Humans
Administration, Oral
Stroke prevention & control
Stroke etiology
Stroke epidemiology
Thromboembolism prevention & control
Thromboembolism etiology
Thromboembolism epidemiology
Hemorrhage chemically induced
Hemorrhage epidemiology
Septal Occluder Device
Atrial Fibrillation complications
Atrial Fibrillation drug therapy
Atrial Appendage surgery
Anticoagulants therapeutic use
Anticoagulants administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1535-6280
- Volume :
- 50
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Current problems in cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 39395644
- Full Text :
- https://doi.org/10.1016/j.cpcardiol.2024.102880